PharmaEssentia Corporation
TAI: 6446.TW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Ko-Chung Lin
- Employees
- 342
- Headquarters
- Taipei, Taiwan
- IPO year
- 2014
- Market cap
- NT$268.7B
- Website
- https://www.pharmaessentia.com
Loading 6446…
Loading profile data…Frequently asked questions about 6446
What does PharmaEssentia Corporation (6446.TW) do?
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develo...
Where does 6446.TW trade?
PharmaEssentia Corporation (6446.TW) trades on the Taiwan Stock Exchange.
What sector is 6446.TW in?
PharmaEssentia Corporation (6446.TW) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of PharmaEssentia Corporation?
Ko-Chung Lin is the chief executive officer of PharmaEssentia Corporation (6446.TW).
Where is PharmaEssentia Corporation headquartered?
PharmaEssentia Corporation is headquartered in Taiwan.
Does 6446.TW pay a dividend?
Yes — PharmaEssentia Corporation (6446.TW) paid a trailing twelve-month dividend of TWD 0.99 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 6446.TW go public?
PharmaEssentia Corporation (6446.TW) completed its initial public offering in 2014.